Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

All Drugs and Chemicals

Vaccines

Estrogens

Immunomodulating Agents

Monatide (IMS 3015)

200 mcg ESR1 peptides plus 1ml Montanide and 100 mcg GM-CSF administered subcutaneously weeks 0, 1, 2, 4, 5, 6 for a total of 6 injections.

ESR1 peptide vaccine

Amy Hobeika, PhD

Stacy Murray, BA, CCRP

H. Kim Lyerly, MD

This is a phase I study looking at the safety of cancer peptides combined with adjuvant and GM-CSF in subjects with estrogen receptor (ESR) positive breast cancer. The primary objective of the study is to determine the safety of of the peptide vaccine. The secondary objective is to evaluate the immune response to the vaccine. The peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. A peptide vaccine of these peptides may improve outcomes of patients with endocrine resistant breast cancer.

Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer

A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer

Herbert Lyerly

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer	NCT04270149	Breast Cancer	ESR1 peptide va...	18 Years -	Duke University
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer	NCT04270149	Breast Cancer	ESR1 peptide va...	18 Years -	Duke University

Spots Global Cancer Trial Database for esr1 peptide vaccine